We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.
hypersensitivity
carboplatin
hypersensitivity
CBDCA
hypersensitivity
paclitaxel